Earnings summaries and quarterly performance for AEON Biopharma.
Executive leadership at AEON Biopharma.
Board of directors at AEON Biopharma.
Research analysts covering AEON Biopharma.
Recent press releases and 8-K filings for AEON.
AEON Biopharma Reports FDA Meeting and Shareholder Approval of November Transactions
AEON
Proxy Vote Outcomes
New Projects/Investments
- AEON Biopharma held a BPD Type 2a Meeting with the FDA on January 21, 2026, for its biosimilar candidate ABP-450 and is awaiting official meeting minutes.
- Shareholders approved the transactions announced in November, including a private investment in public equity (PIPE) financing and the exchange of convertible notes with Daewoong Pharmaceutical Co., Ltd..
- The Daewoong note exchange closed on January 21, 2026, reducing outstanding debt and simplifying the capital structure, resulting in 24,024,282 shares of Common Stock outstanding.
- The second closing of the PIPE financing is expected around January 27, 2026, involving the issuance of 4,616,924 shares (or pre-funded warrants) and 6,581,829 warrants.
Jan 21, 2026, 9:06 PM
AEON Biopharma Provides Update on ABP-450 Biosimilar Development
AEON
New Projects/Investments
- AEON Biopharma, Inc. made available a Corporate Presentation dated January 2026 detailing its strategy for ABP-450, a biosimilar to BOTOX®.
- ABP-450 is being developed to be clinically indistinguishable from BOTOX®, aiming for full label extrapolation to match BOTOX®'s broad clinical indications.
- Analytical data shows 100% amino acid sequence identity for ABP-450 to BOTOX® and highly similar potency across independent assays.
- AEON has a BPD Type 2a meeting with the FDA scheduled for January 21, 2026, to discuss initial analytical data and the path forward for ABP-450.
Jan 12, 2026, 2:17 PM
AEON Biopharma and Daewoong Pharmaceutical Execute Debt Exchange Agreement
AEON
Debt Issuance
New Projects/Investments
- AEON Biopharma, Inc. and Daewoong Pharmaceutical Co., Ltd. executed an Exchange Agreement on December 15, 2025, to exchange AEON's outstanding senior secured convertible notes held by Daewoong.
- The exchange involves $15 million of convertible notes plus accrued interest.
- As consideration, Daewoong will receive new equity (estimated at 23.1 million shares or pre-funded warrants), a new $1.5 million convertible note due 2030, and a warrant to purchase 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share.
- The transaction is subject to stockholder approval and is expected to eliminate more than 90% of AEON's outstanding debt.
Dec 15, 2025, 9:11 PM
AEON Biopharma Reports Positive Biosimilarity Data and Secures Strategic Financing
AEON
Debt Issuance
New Projects/Investments
- AEON Biopharma, Inc. announced positive biosimilarity data for ABP-450 in November 2025, demonstrating 100% amino acid sequence identity to BOTOX® and highly similar potency, which strengthens its position for an upcoming FDA Type 2a meeting on January 21, 2026.
- The company secured $6 million in initial funding through a PIPE financing in November 2025, with potential for over $7 million from warrant exercises.
- AEON also announced the conversion of Daewoong convertible notes in November 2025, which simplifies the balance sheet and provides potential for over $8 million from warrant exercises, exchanging approximately $19.3 million in note amount for common stock, warrants, and a new $1.5 million note.
- These financial and scientific advancements are intended to accelerate the development of ABP-450, a biosimilar targeting the over $3.2 billion U.S. therapeutic toxin market currently dominated by BOTOX®.
Dec 4, 2025, 2:02 PM
AEON Biopharma Reports Q3 2025 Results, Positive Biosimilarity Data, and Strategic Financing
AEON
Earnings
Guidance Update
New Projects/Investments
- AEON Biopharma reported a net loss of $(4,538) thousand and basic net loss per share of $(0.39) for the third quarter ended September 30, 2025.
- The company announced positive biosimilarity data for ABP-450, its proposed biosimilar to BOTOX®, in November 2025, confirming identical amino-acid sequencing and highly similar functional characteristics.
- A Type 2a meeting with the FDA is scheduled for November 19, 2025, to review the analytical development plan and initial data for ABP-450.
- In November 2025, AEON announced two financing transactions, including a $6 million PIPE financing and a proposed note exchange, which are expected to reduce outstanding debt by over 90% and extend the cash runway into the second quarter of 2026.
- As of September 30, 2025, AEON reported cash and cash equivalents of $5.9 million.
Nov 14, 2025, 1:31 PM
AEON Biopharma Reports Q3 2025 Results and Positive ABP-450 Biosimilarity Data
AEON
Earnings
Debt Issuance
New Projects/Investments
- AEON Biopharma reported a net loss of $4.538 million for the three months ended September 30, 2025.
- The company announced positive biosimilarity data for ABP-450, its proposed biosimilar to BOTOX®, confirming identical amino-acid sequencing and highly similar functional characteristics, with an FDA Type 2a meeting scheduled for November 19, 2025.
- As of September 30, 2025, AEON Biopharma held $5.9 million in cash and cash equivalents.
- Two financing transactions, including a $6 million PIPE financing and a proposed Daewoong note exchange, are expected to reduce outstanding debt by over 90% and extend the cash runway into the second quarter of 2026.
Nov 14, 2025, 1:30 PM
AEON Biopharma enters private placement and debt exchange agreements
AEON
Debt Issuance
Convertible Preferred Issuance
- AEON Biopharma, Inc. entered into a Securities Purchase Agreement on November 12, 2025, for a private placement aimed at raising approximately $6 million through the sale of Class A common stock or pre-funded warrants and common warrants to investors.
- Concurrently, AEON entered a Binding Term Sheet with Daewoong Pharmaceutical Co., Ltd. on November 12, 2025, to exchange existing senior secured convertible notes with a principal amount totaling $15 million.
- As part of this exchange, Daewoong will receive a new senior secured convertible note for $1.5 million maturing on April 12, 2030, shares of common stock or pre-funded warrants, and 8,000,000 Daewoong Warrants.
- The securities offered in both the private placement and the debt exchange are being sold under a private placement exemption and have not been registered under the Securities Act.
Nov 13, 2025, 1:30 PM
AEON Biopharma Reports Positive Biosimilarity Results for ABP-450
AEON
Product Launch
New Projects/Investments
- AEON Biopharma announced positive and robust biosimilarity results for ABP-450 (prabotulinumtoxinA) compared to BOTOX (onabotulinumtoxinA).
- The results confirm 100% amino acid sequence identity between ABP-450 and BOTOX, along with highly similar functional analysis data in potency and composition.
- These findings were submitted to the U.S. Food and Drug Administration (FDA) in advance of a scheduled Biosimilar Biological product Development (BPD) Type 2a meeting on November 19, 2025.
- ABP-450 is already approved in 69 countries and manufactured at commercial scale, positioning AEON to potentially become the first full label therapeutic biosimilar to BOTOX in the U.S. therapeutic neurotoxin market, which exceeds $3 billion annually.
Nov 13, 2025, 1:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more